Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Travere

Why Top 4% Stock Travere Therapeutics Skyrocketed To A Three-Year High

Shares of Travere Therapeutics shot higher Wednesday after the FDA eliminated a key step to a new approval for its drug, Filspari.

Investors Business Daily

Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch

Travere Therapeutics shares rose Thursday after the FDA altered monitoring requirements for its drug, Filspari.

Investors Business Daily

Travere Therapeutics Draws Institutional Interest from Armistice Capital, Driehaus, and Wellington

Armistice Capital holds 8.9M shares in Travere Therapeutics as rare kidney disease stock climbs 110% following FILSPARI's full FDA approval.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Stock Market Winners Look A Lot Alike: How To Use IBD's EPS Rating To Find Them

There's plenty of stock market winners that can perform well even if their EPS Rating isn't quite up to snuff.

Investors Business Daily

Travere Therapeutics Rallies To Buy Point As Kidney Drug Sales Rocket 182%; Anticipates FDA Priority Review For FSGS Treatment

Travere Therapeutics stock reported first quarter results on May 1. The company provides drugs to treat rare diseases.

Investors Business Daily

Novartis Has A Slight Edge On Travere — Why Analysts Aren't Worried

Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

Investors Business Daily

IBD Stock Of The Day Travere Therapeutics: A Breakout And $1 Billion Opportunity Loom

Travere Therapeutics is Friday's IBD Stock Of The Day. The biotech stock is eyeing two potential entries and a second approval for Filspari.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug

Travere Therapeutics reached an agreement Tuesday on what data the FDA would require to approve its drug for a kidney disease.

Investors Business Daily

Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level

Kidney disease leader Travere Therapeutics is pulling back to a key support level on the stock market today.

Investors Business Daily

Travere Therapeutics Hits 16-Month High On A Promising FDA 'Pivot' In Kidney Disease

Travere Therapeutics stock popped Wednesday after a group of experts suggested an alternative means of measuring the success of FSGS drugs.

Investors Business Daily

Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease

Travere Therapeutics stock surged Friday after the biotech company snagged full FDA approval for its kidney disease treatment, Filspari.

Investors Business Daily

Why Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Low

Travere said Thursday its kidney disease drug failed to pass muster in a confirmatory study, and TVTX stock crashed to a 10-year low.

Investors Business Daily

Travere Crashes 31% On A Potential Yearlong Delay For Its Kidney Disease Drug

Travere Therapeutics offered a disappointing update from a two-year study in kidney disease, and TVTX stock crashed Tuesday.

Investors Business Daily

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares…

Investors Business Daily

Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug

The FDA accepted Travere Therapeutics' application for a kidney disease treatment on Monday, leading TVTX stock to surge higher.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.